Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses by Alain H. Rook, Gary S. Wood, Elisa K. Yoo,

Slides:

Advertisements

Similar presentations

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):

Advertisements

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,

Copyright © 2005 American Medical Association. All rights reserved.

Dose-escalation patient response.

The beauty of TLR agonists for CTCL

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy by Massimo Massaia, Paolo Borrione, Silvano.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

How I treat elderly patients with myeloma

Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells by Lucie Heinzerling,

Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)‏ by Nicolas.

First successful treatment of a primary high-grade gastric MALT lymphoma by eradication therapy for Helicobacter pylori Stephan Timm, Marco Sailer, Karl–hermann.

by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C

T regulatory cells turn on T regulatory cells

TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for.

A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.

Fusion genes in cord blood

Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions by Alexander G.

Deep mining of the RBC proteome

Effect of a Recombinant Dimeric Tumor Necrosis Factor Receptor on Inflammatory Responses to Intravenous Endotoxin in Normal Humans by Tom van der Poll,

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15 by Maria Wysocka, Bernice M. Benoit, Sarah.

by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B

Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index by Chor-Sang Chim, Shing-Yan.

Latest lymphoma classification is skin deep

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients by Arthur E. Frankel,

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report by Richard L.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Treatment of 7 patients with relapsed/refractory NK/T-cell lymphomas treated with pembrolizumab. Treatment of 7 patients with relapsed/refractory NK/T-cell.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Volume 4, Issue 7, Pages (August 2018)

Volume 24, Issue 8, Pages (August 2016)

The PPAR-α agonist GW7647 reduces experimentally induced myopia.

Volume 18, Issue 2, Pages (February 2010)

by Geling Li, Emily Waite, and Julie Wolfson

Hong Wu, Mitchell Smith, Michael M

T Cell Receptor γ-Chain Gene Polymerase Chain Reaction to Diagnose Central Nervous System Involvement by Cutaneous T Cell Lymphoma Robert Taylor, Jo-Anne.

Evaluation of clinical responses after infusion of CART19 cells

by Hannah L Bader, Tracy Pritchett, and Tien Hsu

Clonotypic heterogeneity in cutaneous T-cell lymphoma (mycosis fungoides) revealed by comprehensive whole-exome sequencing by Aishwarya Iyer, Dylan Hennessey,

Volume 24, Issue 8, Pages (August 2016)

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase by Yok-Lam Kwong, Thomas S. Y.

Variable CD7 Expression on T Cells in the Leukemic Phase of Cutaneous T Cell Lymphoma (Sézary Syndrome) Eric C. Vonderheid, Amy Kotecha, Christine M.

CR-rate ratios with 95% CIs

Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to minimum observed white blood cell.

Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma by Bethany Mundy-Bosse, Nathan Denlinger,

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium.

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

Evaluation of clinical responses after infusion of CART19 cells

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

by Jan J. Cornelissen, and Didier Blaise

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

by Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J

Changes from baseline in (A) sputum cellularity and (B) endobronchial biopsy cellularity following 1 year of single maintenance and reliever therapy (SMART)

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Is Skull-Base to Proximal Thigh PET/CT Enough

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Treatment-induced immune cell changes.

A, Recurrent neoplasm in patient 6.

Presentation transcript:

Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses by Alain H. Rook, Gary S. Wood, Elisa K. Yoo, Rosalie Elenitsas, David M.F. Kao, Matthew L. Sherman, William K. Witmer, Kenneth A. Rockwell, Ryan B. Shane, Stuart R. Lessin, and Eric C. Vonderheid Blood Volume 94(3):902-908 August 1, 1999 ©1999 by American Society of Hematology

CRs of 2 patients during treatment with rhIL-12. CRs of 2 patients during treatment with rhIL-12. (A) Patient 7 before starting rhIL-12. (B) Patient 7 at the conclusion of treatment with rhIL-12 showing complete clearing of skin lesions on the trunk. (C) Patient 6 before initiating rhIL-12. (D) The same patient at week 10 of therapy with complete clearing of skin lesions. Alain H. Rook et al. Blood 1999;94:902-908 ©1999 by American Society of Hematology

Intralesional injections of rhIL-12 result in tumor regression. Intralesional injections of rhIL-12 result in tumor regression. (A) Tumor of the right forearm at baseline in patient 5. (B) Complete flattening of the tumor at week 3 after 6 injections of rhIL-12 at a dose of 100 ng/kg into the tumor. Histologic examination of the flattened tumor showed complete resolution of the malignant infiltrate. Alain H. Rook et al. Blood 1999;94:902-908 ©1999 by American Society of Hematology

CD3+ cells within involved skin lesions decrease during lesion regression while receiving rhIL-12. CD3+ cells within involved skin lesions decrease during lesion regression while receiving rhIL-12. (A) Biopsy specimen of involved skin from patient 6 at baseline. (B) Biopsy specimen of same lesion as in (A) when lesion was nearly completely resolved during rIL-12 treatment. Alain H. Rook et al. Blood 1999;94:902-908 ©1999 by American Society of Hematology

TIA-1+ cells increase significantly within regressing skin lesions during rhIL-12 treatment. TIA-1+ cells increase significantly within regressing skin lesions during rhIL-12 treatment. (A) Involved skin at baseline from patient 8 with small numbers of TIA-1+cells as indicated by the arrow. (B) A 2- to 3-fold increase in the proportion of TIA-1+ cells as indicated by the arrows within the same lesion during regression associated with rhIL-12 treatment. Alain H. Rook et al. Blood 1999;94:902-908 ©1999 by American Society of Hematology